Repair & recovery
LL-37
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Also known as Cathelicidin fragment
A human antimicrobial peptide studied for immune modulation, biofilm disruption and wound repair.
What it is
LL-37 is the active fragment of the human cathelicidin protein, part of innate immune defense. Research examines direct antimicrobial activity, biofilm disruption and the recruitment of immune cells to injured or infected tissue.
What it's studied for
- Bacterial and biofilm activity in laboratory models
- Chronic wound healing
- Immune-signaling balance
How it's used in practice
- Discussed in research contexts involving persistent, treatment-resistant inflammation
- Vitamin D status influences endogenous LL-37 production
What you should know before asking about it
- Research use only, not FDA-approved
- Can be pro-inflammatory as well as anti-inflammatory depending on context
- Should never replace evaluation for an actual infection
Frequently asked questions.
- What is LL-37?
- LL-37 is the active fragment of the human cathelicidin protein, part of innate immune defense. Research examines direct antimicrobial activity, biofilm disruption and the recruitment of immune cells to injured or infected tissue.
- What is LL-37 studied for?
- Published and ongoing research looks at bacterial and biofilm activity in laboratory models; chronic wound healing; immune-signaling balance. These are areas of study, not promised outcomes.
- Is LL-37 FDA-approved?
- LL-37 has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
- How is LL-37 typically used?
- Discussed in research contexts involving persistent, treatment-resistant inflammation Vitamin D status influences endogenous LL-37 production Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with LL-37?
- Research use only, not FDA-approved Can be pro-inflammatory as well as anti-inflammatory depending on context Should never replace evaluation for an actual infection
Sources
- 1.Published literature on LL-37 Cathelicidin fragment— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Repair & recovery
BPC-157
A synthetic pentadecapeptide sequence studied in preclinical models of tendon, ligament, muscle and gut-lining repair.
TB-500
A fragment of thymosin beta-4 studied for cell migration, flexibility and scar remodeling in preclinical injury models.
GHK-Cu
A naturally occurring copper-binding tripeptide studied for collagen synthesis, skin quality and gene-expression effects.